Induced regulatory T cells in inhibitory microenvironments created by cancer

Bibliography

• Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 2012;22:327-34
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 2012;12:1383-97
   PubMed Web of Science ®Google Scholar
• deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FOXP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012;18:3022-9
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Lanzavecchia A, et al. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 2012;119:4430-40
   PubMed Web of Science ®Google Scholar
• Abbas AK, Benoist C, Bluestone JA, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013;14:307-8
   PubMed Web of Science ®Google Scholar
• Andersen MH, Sørensen RB, Brimnes MK, et al. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest 2009;119(8):2245-56
   PubMed Web of Science ®Google Scholar
• Addey C, White M, Dou L, et al. Functional plasticity of antigen-specific regulatory T cells in context of tumor. J Immunol 2011;186:4557-64
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74
   PubMed Web of Science ®Google Scholar
• Long SA, Buckner JH. CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol 2011;187:2061-6
   PubMed Web of Science ®Google Scholar
• Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol 2013;4:190
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer. Adv Cancer Res 2010;107:57-117
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Macatangay BJ, Saze Z, et al. CD4+CD73+ T cells are associated with lower T cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. AIDS 2013;27:1545-55
   PubMed Web of Science ®Google Scholar
• Canavan JB, Afzali B, Scotta C, et al. A rapid diagnostic test for human regulatory T cell function to enable regulatory T cell therapy. Blood 2012;119:e57-66
   PubMed Web of Science ®Google Scholar
• Ruitenberg JJ, Boyce C, Hingorani R, et al. Rapid assessment of in vitro expanded human regulatory T cell function. J Immunol Methods 2011;372:95-106
   PubMed Web of Science ®Google Scholar
• Piersma SJ, van der Hulst JM, Kwappenberg KM, et al. Influenza matrix 1-specific human CD4+FOXP3+ and FOXP3(-) regulatory T cells can be detected long after viral clearance. Eur J Immunol 2010;40:3064-74
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associated with longer patient survival. Nat Med 2012;18:1254-61
   PubMed Web of Science ®Google Scholar
• Vukmanovic-Stejic M, Zhang Y, Cook JE, et al. Human CD4+ CD25hi FOXP3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006;116:2423-33
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FOXP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-11
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski M, Harasymczuk M, et al. CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology 2012;1:659-69
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Whiteside TL. Functional and phenotypic characteristics of CD4+CD25highFOXP3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 2007;121:2473-83
   PubMed Web of Science ®Google Scholar
• Fazilleau N, Bachelez H, Gougeon ML, Viguier M. Cutting edge: size and diversity of CD4+CD25high FOXP3+ regulatory T cell repertoire in humans: evidence for similarities and partial overlapping with CD4+CD25- T cells. J Immunol 2007;179:3412-16
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FOXP3. Science 2003;299:1057-61
   PubMed Web of Science ®Google Scholar
• Beyer M, Thabet Y, Muller RU, et al. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol 2011;12:898-907
   PubMed Web of Science ®Google Scholar
• McInnes N, Sadlon TJ, Brown CY, et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene 2012;31:1045-54
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Schilling B, Harasymczuk M, et al. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T cell subsets in cancer patients. Eur J Immunol 2012;42:1876-85
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Wang Y, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008;14:3706-15
   PubMed Web of Science ®Google Scholar
• Elkord E, Al-Ramadi BK. Helios expression in FoxP3(+) T regulatory cells. Expert Opin Biol Ther 2012;12:1423-5
   PubMed Web of Science ®Google Scholar
• Raffin C, Pignon P, Celse C, et al. Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functions. J Immunol 2013;191:4619-27
   PubMed Web of Science ®Google Scholar
• Himmel ME, MacDonald KG, Garcia RV, et al. Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol 2013;190:2001-8
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski MJ, et al. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008;180(5):2967-80
   PubMed Web of Science ®Google Scholar
• Zaunders JJ, Munier ML, Seddiki N, et al. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol 2009;183:2827-36
   PubMed Web of Science ®Google Scholar
• Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol 2012;188:892-901
   PubMed Web of Science ®Google Scholar
• Milpied P, Renand A, Bruneau J, et al. Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur J Immunol 2009;39(6):1466-71
   PubMed Web of Science ®Google Scholar
• Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother 2014;63:81-99
   PubMed Web of Science ®Google Scholar
• Ondondo B, Jones E, Godkin A, Gallimore A. Home sweet home: the tumor microenvironment as a haven for regulatory T cells. Front Immunol 2013;4:197
   PubMed Web of Science ®Google Scholar
• Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008;111:453-62
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Hilldorfer B, Szczepanski MJ, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 2010;285:7176-86
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Saze Z, Hong CS, et al. Human CD4(+) CD39(+) regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73(+) exosomes or CD73(+) cells. Clin Exp Immunol 2014, doi: 10.1111/cei.12354. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Stockis J, Colau D, Coulie PG, Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 2009;39:3315-22
   PubMed Web of Science ®Google Scholar
• Tran DQ, Andersson J, Wang R, et al. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009;106:13445-50
   PubMed Web of Science ®Google Scholar
• Sun J, Tang DN, Fu T, Sharma P. Identification of human regulatory T cells in the setting of T cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov 2012;2:122-30
   Google Scholar
• Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 2009;182:1469-80
   PubMed Web of Science ®Google Scholar
• Czystowska M, Strauss L, Bergmann C, et al. Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med (Berl) 2010;88:577-88
   PubMed Web of Science ®Google Scholar
• Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-32
   PubMed Web of Science ®Google Scholar
• Cheng G, Yu A, Malek TR. T cell tolerance and the multi-functional role of IL-2R signaling in T regulatory cells. Immunol Rev 2011;241:63-76
   PubMed Web of Science ®Google Scholar
• Cheng G, Yu A, Dee MJ, Malek TR. IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development. J Immunol 2013;190:1567-75
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-700
   PubMed Web of Science ®Google Scholar
• Lopez CB, Rao TD, Feiner H, et al. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cell Immunol 1998;190:141-55
   PubMed Web of Science ®Google Scholar
• Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009;30:204-17
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Gooding W, et al. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6301-11
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72
   PubMed Web of Science ®Google Scholar
• Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007;8:1353-62
   PubMed Web of Science ®Google Scholar
• Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-66
   PubMed Web of Science ®Google Scholar
• Saadoun D, Rosenzwaig M, Joly F, et al. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-77
   PubMed Web of Science ®Google Scholar
• Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30(6):899-911
   PubMed Web of Science ®Google Scholar
• Rech AJ, Mick R, Martin S, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012;4:134ra62
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Harasymczuk M, Schilling B, et al. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res 2013;19:6585-96
   PubMed Web of Science ®Google Scholar
• Oida T, Weiner HL. Overexpression of TFG-β 1 gene induces cell surface localized glucose-regulated protein 78-associated latency-associated peptide/TGF-β. J Immunol 2010;185:3529-35
   PubMed Web of Science ®Google Scholar
• Zhang L, Bertucci AM, Ramsey-Goldman R, et al. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol 2009;183:6346-58
   PubMed Web of Science ®Google Scholar
• Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146
   PubMed Web of Science ®Google Scholar
• Rubtsov YP, Rudensky AY. TGFbeta signaling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007;7:443-53
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000;12:171-81
   PubMed Web of Science ®Google Scholar
• Mempel TR, Pittet MJ, Khazaie K, et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 2006;25:129-41
   Google Scholar
• Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kitani A, Fuss I, et al. TGF-beta 1 plays an important role in the mechanisms of CD4+CD24+ regulatory T cell activity in both humans and mice. J Immunol 2004;172:834-42
   PubMed Web of Science ®Google Scholar
• Andersson J, Tran DQ, Pesu M, et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 2008;205:1975-81
   PubMed Web of Science ®Google Scholar
• White RA, Malkoski SP, Wang XJ. TGF-beta signaling in head and neck squamous cell carcinoma. Oncogene 2010;29:5437-46
   PubMed Web of Science ®Google Scholar
• Sitkovksy MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2008;30:102-8
   Web of Science ®Google Scholar
• Regateiro FS, Howie D, Nolan KF, et al. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-beta. Eur J Immunol 2011;41:2955-65
   PubMed Web of Science ®Google Scholar
• Hasko G, Linden J, Cronstein Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759-70
   PubMed Web of Science ®Google Scholar
• Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013;13:842-57
   PubMed Web of Science ®Google Scholar
• Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010;30:5346-58
   Google Scholar
• Zhou X, Zhi X, Zhou P, et al. Effects of ecto-5’-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep 2007;17:1341-6
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Jackson EK. Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol 2013;4:212
   PubMed Web of Science ®Google Scholar
• Su Y, Huang X, Raskovalova T, et al. Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother 2008;57:1611-23
   PubMed Web of Science ®Google Scholar
• Su Y, Jackson EK, Gorelik E. Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother 2011;60:111-22
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 2012;61:283-8
   PubMed Web of Science ®Google Scholar
• Muller-Haegele S, Muller L, Whiteside TL. Immunoregulatory activity of adenosine and its role in human cancer progression. Exp Rev Clin Immunol. In press 2014
   Google Scholar
• Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by FoxP3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-32
   PubMed Web of Science ®Google Scholar
• Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-65
   PubMed Web of Science ®Google Scholar
• Ohta A, Kini R, Ohta A, et al. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 2012;3:190
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski MJ, Szajnik M, et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010;285:27571-80
   PubMed Web of Science ®Google Scholar
• Kinsey GR, Huang L, Jaworska K, et al. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol 2012;23(9):1528-37
   PubMed Web of Science ®Google Scholar
• Delgoffe GM, Woo SR, Turnis ME, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 2013;501:252-6
   PubMed Web of Science ®Google Scholar
• Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004;4:665-74
   PubMed Web of Science ®Google Scholar
• Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 2010;70:2245-55
   PubMed Web of Science ®Google Scholar
• Bastid J, Cottalorda-Regairaz A, Alberici G, et al. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2013;32:1743-51
   PubMed Web of Science ®Google Scholar
• Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012;72:3439-44
   PubMed Web of Science ®Google Scholar
• Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009;1174:99-106
   PubMed Web of Science ®Google Scholar
• Baur AS, Lutz MB, Schierer S, et al. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg. Blood 2013;122:2185-94
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
   PubMed Web of Science ®Google Scholar
• Elkord E, Alcantar-Orozco EM, Dovedi SJ. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 2010;10:1573-86
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Igbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 2010;3:15-25
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73:3591-603
   PubMed Web of Science ®Google Scholar
• Camisaschi C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010;184:6545-51
   PubMed Web of Science ®Google Scholar
• Yan J, Zhang Y, Zhang JP, et al. Tim-3 expression defines regulatory T cells in human tumors. PLoS One 2013;8:e58006
   PubMed Web of Science ®Google Scholar
• Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012;7:e30676
   PubMed Web of Science ®Google Scholar
• Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013;109:2629-35
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yahita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells with B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107:4275-80
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010;10:1019-35
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. The role of anti-inflammatory drugs in colorectal cancer. Annu Rev Med 2013;64:131-44
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Zeidler R, et al. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007;67:8865-73
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Whiteside TL. Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E2 cooperation. Expert Opin Biol Ther 2011;11:1203-14
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski MJ, Szajnik M, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 2009;15:6348-57
   PubMed Web of Science ®Google Scholar
• Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010;107:1547-52
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou X, Zhou T, et al. Ecto-5’-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 2008;134:365-72
   PubMed Web of Science ®Google Scholar
• Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013;19:355-67
   PubMed Web of Science ®Google Scholar
• Allard B, Turcotte M, Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012;2012:485156
   PubMedGoogle Scholar
• Sim GC, Martin-Orozco N, Jin L, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014;124:99-110
   PubMed Web of Science ®Google Scholar
• Eggermont AM. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 2009;15:6745-7
   Google Scholar
• Kuss I, Hathaway B, Ferris RL, et al. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;10:3755-62
   Google Scholar
• Rech AJ, Mick R, Kaplan DE, et al. Homeostasis of peripheral FoxP3(+) CD4(+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 2010;59:599-607
   PubMed Web of Science ®Google Scholar
• Schaue D, Xie MW, Ratikan JA, McBride WH. Regulatory T cells in radiotherapeutic responses. Front Oncol 2012;2:90
   PubMedGoogle Scholar
• Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7:880-7
   PubMed Web of Science ®Google Scholar
• Moltedo B, Hemmers S, Rudensky AY. Regulatory T cell ablation causes acute T cell lymphopenia. PLoS One 2014;9:e86762
   Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014;27C:1-7
   Google Scholar
• Burocchi A, Colombo MP, Piconese S. Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol 2013;4:247
   PubMed Web of Science ®Google Scholar
• Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol 2013;4:152
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Visus C, Finn OJ, et al. Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells. Oncoimmunology 2013;2:e25514
   Google Scholar
• Houot R, Goldstein MJ, Kohrt HE, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009;114(16):3431-8
   PubMed Web of Science ®Google Scholar
• Polansky JK, Shreiber L, Thelemann C, et al. Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J Mol Med (Berl) 2010;88:1029-40
   PubMed Web of Science ®Google Scholar